Kerala Cabinet announces pay hike for govt lawyers, aid for Nipah patient
The Kerala Cabinet has approved a pay raise for government lawyers, benefiting District Government Pleaders, Public Prosecutors, and other legal professionals, effective retroactively from January 1, 2022. Financial assistance of Rs 17 lakh was sanctioned from the Chief Minister's Relief Fund for Titto Thomas, a health worker battling Nipah encephalitis.
Agencies Pinarayi Vijayan The Kerala Cabinet chaired by Chief Minister Pinarayi Vijayan on Wednesday approved a set of decisions benefiting government lawyers, a severely ill health worker, and a local sports facility in Thalassery.According to a CMO release, government lawyers across the state will receive a pay rise.The monthly remuneration for District Government Pleaders and Public Prosecutors will increase from Rs 87,500 to Rs 1.10 lakh, while Additional Government Pleaders and Additional Public Prosecutors will see their pay go up from Rs 75,000 to Rs 95,000.Pleaders engaged for government work will get Rs 25,000 a month, up from Rs 20,000. The revision will take effect retroactively from January 1, 2022, it said.In another decision, the Cabinet sanctioned Rs 17 lakh from the Chief Minister's Relief Fund to support Titto Thomas, a health worker who has been unconscious for more than a year after contracting Nipah encephalitis in 2023.
He continues to receive treatment at a private hospital in Kozhikode, the release said.The Cabinet also decided to lease the V R Krishna Iyer Memorial Stadium in Thalassery to the local municipality for 10 years, under strict conditions.The government said the stadium can be used only for sports-related activities, and commercial establishments will require prior government approval.A coordination committee, led by the municipal chairman and representatives from the sports and revenue departments, will manage the facility.
The Sports Department will have free access for official events, while other departments and organisations may use it for sports at reasonable rates, the release added.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
30 minutes ago
- Time of India
Apollo Hospitals shares in focus as brokerages hike target prices post strong Q1FY26 results
Apollo Hospitals shares are likely to be in focus on Thursday, August 14, after the company posted a strong set of Q1FY26 results , prompting multiple brokerage firms to raise their target prices for the stock. The healthcare major reported a consolidated net profit of Rs 433 crore for the quarter ended June 30, 2025, marking a 42% year-on-year increase from Rs 305 crore in the same period last year. On a sequential basis, PAT was up 11% from Rs 390 crore in Q4FY25. Finance Value and Valuation Masterclass - Batch 4 By CA Himanshu Jain View Program Artificial Intelligence AI For Business Professionals Batch 2 By Ansh Mehra View Program Finance Value and Valuation Masterclass - Batch 3 By CA Himanshu Jain View Program Artificial Intelligence AI For Business Professionals By Vaibhav Sisinity View Program Finance Value and Valuation Masterclass - Batch 2 By CA Himanshu Jain View Program Finance Value and Valuation Masterclass Batch-1 By CA Himanshu Jain View Program Revenue from operations in Q1FY26 rose 15% year-on-year to Rs 5,842 crore compared to Rs 5,086 crore in Q1FY25. Sequentially, revenue grew 4.5% from Rs 5,592 crore in the March quarter. The robust performance was supported by growth across segments, improved specialty mix, and operational efficiency gains. Nuvama: Buy| Target price: Rs 9,010 Nuvama has raised its target price for Apollo Hospitals to Rs 9,010 from Rs 8,635, maintaining a 'Buy' rating. Live Events The brokerage noted strong performance from HealthCo and said sustained execution remains key. It expects hospital growth from H2FY26 through phased bed expansion, higher international patient inflows, and an improved specialty mix. Nuvama also highlighted potential value unlocking from the Keimed merger, front-end restructuring, and a possible listing within 18 months. HealthCo's valuation multiple was raised to 26x from 22x, and FY26E/FY27E EBITDA estimates were increased by 2% and 4%, respectively. Motilal Oswal: Buy| Target price: Rs 9,010 Motilal Oswal also raised its target price to Rs 9,010 from Rs 8,720 while maintaining a 'Buy' rating. The firm cited broad-based growth with EBITDA and PAT beating estimates on cost optimisation and noted that profitability was boosted by lower operating expenses. It highlighted a 14% year-on-year rise in surgical revenues on the back of strong CONGO therapy momentum. HealthCo is on track for cash EBITDA breakeven (excluding ESOP) by Q2FY26/Q3FY26. The brokerage expects 15%, 21%, and 28% CAGR in revenue, EBITDA, and PAT, respectively, over FY25–FY27 and has raised its FY26/FY27 earnings estimates by 7%. Avendus: Buy| Target price: Rs 8,765 Avendus has increased its target price for Apollo Hospitals to Rs 8,765 from Rs 8,515, reiterating a 'Buy' call. The brokerage has advanced the breakeven timeline for the online business EBITDA to FY27 from FY28 earlier. It projects ex-Keimed revenue CAGR at 17% in FY25–FY27, with EBITDA expected at Rs 510 crore and Rs 770 crore for FY26 and FY27, respectively. Offline pharmacy revenue CAGR is also projected at 17%, while existing units' EBITDA CAGR is estimated at 16% in the same period. Avendus factors in the AHCo–Keimed merger in April 2026 and the APL front-end acquisition in April 2027. It expects healthcare services EBITDA CAGR of 14% and AHLL at 22% over FY25–FY27. FY26/FY27 EBITDA estimates have been raised by 4% each, driven by higher AHCo EBITDA, partly offset by new hospital losses. Also read: Zerodha's Nithin Kamath on how a boring, invisible Sebi step brought windfall gains for retail investors ( Disclaimer : Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)
Hans India
3 hours ago
- Hans India
Balakrishna launches Basavatarakam cancer hospital works
Vijayawada: The construction of a new, state-of-the-art cancer care campus for Basavatarakam Indo-American Cancer Hospital & Research Institute (BIACH&RI) has officially begun in, a part of Andhra Pradesh's capital region. The foundation stone was laid on Wednesday by the hospital's chairman, Nandamuri Balakrishna, in a traditional puja ceremony. The project, which faced significant delays after its initial foundation stone was laid in 2019, is now moving forward following the new state government's decision to clear all hurdles and allot an additional six acres of land. The new facility will be built on a total of 21 acres. Speaking at the launch, Balakrishna explained that the new campus is envisioned as a 'Centre of Excellence' for comprehensive cancer treatment, research, and patient care. The facility will integrate cutting-edge medical technology with a multidisciplinary approach. Balakrishna explained that the new facility is envisioned as a Centre of Excellence for comprehensive cancer treatment, research, and patient-centric care. The hospital will integrate cutting-edge medical technology with a multidisciplinary approach, delivered in a purpose-built modern facility, he added. An initial investment of Rs 750 crore will establish a 500-bed facility, offering a broad spectrum of oncology services in the first phase. This phase will focus on infrastructure, advanced equipment, and clinical excellence, including precision diagnostics and treatment systems. Operations are expected to commence by 2028. The second phase will add another 500 beds, bringing the total capacity to 1,000. It will include the development of specialised departments, research wings, and enhanced patient amenities, with the goal of creating a regional referral center for complex cancer cases. The launch event was attended by several dignitaries, including Assembly Speaker Ch Ayyanna Patrudu, ministers P Narayana and Y Satya Kumar, along with MP Kesineni Shivnath, MLA Tenali Sravan Kumar, Dr Undavalli Sridevi and other prominent leaders and officials. Trust board members, including Dr Dattatreyudu Nori and Nara Brahmani, were also present. In his remarks, Balakrishna expressed his gratitude to all donors and supporters, emphasising that the project would carry forward the hospital's legacy of compassion and excellence. Dr. Senthil Rajappa, head of Medical Oncology, assured that medical services at the new facility would be operational by 2028.
Time of India
6 hours ago
- Time of India
In a 1st in India, Goa to negotiate lower prices for life-saving therapies
Representative image PANAJI: In a move aimed at giving people greater access to high-cost medical treatment for cancer and rare diseases, Goa rolled out an innovative pricing policy for life-saving therapies. Under the policy, the state govt will procure drugs, medical equipment, and diagnostics from pharmaceutical firms at a lower negotiated price from the listed price, enabling budget allocation to cater to more patients or support a longer duration for therapies. Vishwajit Rane, health minister, said on Wednesday the govt is the first in the country to adopt this policy framework, which enables confidential pricing agreements between govt and pharmaceutical innovators. The rollout is likely to begin with lung cancer treatment. Innovative therapies for diseases like cancer, rare genetic disorders, and autoimmune conditions can cost upwards of Rs 50 lakh per year, making them difficult for most patients, he said. "Goa's adoption of this pricing policy is a vital and timely step to advance health equity in the state. This value-based approach to pricing will improve access for patients and marks a new era focusing on helping more patients," Rane said. Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like No annual fees for life UnionBank Credit Card Apply Now Undo by Taboola by Taboola This new innovation will prove beneficial to Goa, which is in the upper quartile of the list of highest cancer incidence rates in the country. The state sees around 1,500 new cancer patients every year, which is set to increase by 5% each year, with the most common cancer being breast cancer, accounting for over 300 annual cases, followed by oral cavity cancer, which accounts for 20-25% of all cancers. The healthcare system must be better equipped to handle the growing burden of cancers and rare disease cases, Rane said. A committee chaired by the additional or joint secretary of health and comprising the dean of GMC, director of health services, and pharmacy heads will be constituted to recommend appropriate pricing for approval by govt. The committee will also be empowered to negotiate with firms to secure the best rate for patented drugs and equipment after signing agreements.
